We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+4.47%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$563M
AUM Growth
+$59.4M
Cap. Flow
+$52M
Cap. Flow %
9.23%
Top 10 Hldgs %
30.6%
Holding
102
New
10
Increased
33
Reduced
31
Closed
5

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$14.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.4M
3
BIIB icon
Biogen
BIIB
+$11.1M
4
CELG
Celgene Corp
CELG
+$8.17M
5
ENDP
Endo International plc
ENDP
+$7.77M

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$11.1M
2
STJ
St Jude Medical
STJ
+$9.9M
3
MDVN
MEDIVATION, INC.
MDVN
+$6.07M
4
PRGO icon
Perrigo
PRGO
+$4.25M
5
LH icon
Labcorp
LH
+$3.76M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 1.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$1.97M 0.35%
+130,000
New +$2.14M
RIGL icon
77
Rigel Pharmaceuticals
RIGL
$750M
$1.9M 0.34%
85,000
– –
KYNB
78
Kyntra Bio
KYNB
$29.4M
$1.87M 0.33%
4,560
– –
NBIX icon
79
Neurocrine Biosciences
NBIX
$16.6B
$1.82M 0.32%
40,000
-20,000
-33% -$921K
PRGO icon
80
Perrigo
PRGO
$1.78B
$1.81M 0.32%
20,000
-41,000
-67% -$4.25M
ACAD icon
81
Acadia Pharmaceuticals
ACAD
$5.03B
$1.62M 0.29%
50,000
– –
TNDM icon
82
Tandem Diabetes Care
TNDM
$1.56B
$1.58M 0.28%
20,900
– –
ESPR
83
DELISTED
Esperion Therapeutics
ESPR
$1.38M 0.25%
140,000
-10,000
-7% -$166K
ARRY
84
DELISTED
Array Biopharma Inc
ARRY
$1.32M 0.23%
370,000
– –
TTPH
85
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.29M 0.23%
15,000
– –
ATXS
86
DELISTED
Astria Therapeutics
ATXS
$1.28M 0.23%
5,752
– –
RGLS
87
DELISTED
Regulus Therapeutics
RGLS
$1.01M 0.18%
2,917
+1,250
+75% +$895K
ANTH
88
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$927K 0.16%
37,500
-16,875
-31% -$477K
QHC
89
DELISTED
Quorum Health Corporation
QHC
$602K 0.11%
+56,250
New +$656K
OREX
90
DELISTED
Orexigen Therapeutics, Inc.
OREX
$516K 0.09%
120,000
– –
RARE icon
91
Ultragenyx Pharmaceutical
RARE
$2.55B
$489K 0.09%
10,000
-30,000
-75% -$1.94M
ADVM
92
DELISTED
Adverum Biotechnologies
ADVM
$487K 0.09%
15,401
– –
CNCE
93
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$338K 0.06%
+30,099
New +$383K
MRTX
94
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$273K 0.05%
50,000
– –
OCUL icon
95
Ocular Therapeutix
OCUL
$2.02B
$198K 0.04%
40,000
– –
GKOS icon
96
Glaukos
GKOS
$10.6B
$149K 0.03%
+5,100
New +$118K
MTEM
97
DELISTED
Molecular Templates, Inc.
MTEM
$128K 0.02%
1,221
– –
IONS icon
98
Ionis Pharmaceuticals
IONS
$9.4B
– –
-64,000
Closed -$2.59M
PCRX icon
99
Pacira BioSciences
PCRX
$997M
– –
-40,000
Closed -$2.12M
STJ
100
DELISTED
St Jude Medical
STJ
– –
-180,000
Closed -$9.9M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rhenman & Partners Asset Management held 102 positions worth $563M, up 12% from $504M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rhenman & Partners Asset Management deployed $52M of net new capital in Q2 2016, opening 10 new positions and adding to 33 existing holdings. Its largest new stake was Pediatrix Medical: 80,000 shares worth $5.79M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Alkermes, an estimated $11.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2016 buy was Pediatrix Medical: 80,000 shares worth $5.79M.
  • Rhenman & Partners Asset Management added most to Alexion Pharmaceuticals in Q2 2016, an estimated $14.5M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2016 reduction was Alkermes, cutting an estimated $11.1M.
  • Rhenman & Partners Asset Management fully exited St Jude Medical in Q2 2016, selling an estimated $9.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 31% of its $563M portfolio in Q2 2016.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 5 in Q2 2016.
  • Rhenman & Partners Asset Management's portfolio value rose 12% quarter-over-quarter to $563M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2016, filed 1 Aug 2016.